{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:47:18Z","timestamp":1793677638972,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836042002"],"award-info":[{"award-number":["836042002"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40264-021-01045-3","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T11:03:40Z","timestamp":1612436620000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry"],"prefix":"10.1007","volume":"44","author":[{"name":"IBDREAM registry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline L.","family":"Giraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-4509","authenticated-orcid":false,"given":"Pepijn W. A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette A.","family":"van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene P.","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa E. H.","family":"R\u00f6mkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice G. V. M.","family":"Russel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi T.","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoentjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"issue":"2","key":"1045_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"SS Seyedian","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113\u201322.","journal-title":"J Med Life."},{"issue":"6","key":"1045_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.05.013","volume":"40","author":"C Huttenhower","year":"2014","unstructured":"Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity. 2014;40(6):843\u201354.","journal-title":"Immunity"},{"key":"1045_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S65979","volume":"7","author":"M Fakhoury","year":"2014","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113\u201320.","journal-title":"J Inflamm Res."},{"key":"1045_CR4","unstructured":"A Guideline on Summary of Product Characteristics (SmPC). Directorate-General. European Commission Enterprise and Industry; 2009. p. 29."},{"issue":"7","key":"1045_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","volume":"14","author":"ME de Jong","year":"2020","unstructured":"de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel M, Romkens TEH, et al. Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients. J Crohns Colitis. 2020;14(7):888\u201395.","journal-title":"J Crohns Colitis."},{"key":"1045_CR6","unstructured":"Netherlands Pharmacovigilance Centre Lareb. About Lareb. https:\/\/www.lareb.nl\/en\/pages\/about-lareb. Accessed 2 Jul 2020."},{"key":"1045_CR7","unstructured":"(ICH) Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/. Accessed 14 Apr 2020."},{"key":"1045_CR8","unstructured":"CBG Geneesmiddeleninformatiebank College ter Beoordeling van Geneesmiddelen. https:\/\/www.geneesmiddeleninformatiebank.nl\/nl\/. Accessed 14 Mar 2020."},{"key":"1045_CR9","volume-title":"Summary of product characteristics, Humira","author":"AbbVie","year":"2008","unstructured":"AbbVie. Summary of product characteristics, Humira. Wiesbaden: AbbVie Biotechnology GmbH; 2008."},{"key":"1045_CR10","volume-title":"Summary of product characteristics, azathioprine mylan 25 mg\/50 mg","author":"Mylan","year":"2019","unstructured":"Mylan. Summary of product characteristics, azathioprine mylan 25 mg\/50 mg. Bunschoten: Mylan B.V; 2019."},{"key":"1045_CR11","volume-title":"Summary of product characteristics, Remicade","author":"Janssen-Cilag","year":"2009","unstructured":"Janssen-Cilag. Summary of product characteristics, Remicade. Beerse: Janssen Biologics B.V; 2009."},{"key":"1045_CR12","volume-title":"Summary of product characteristics, puri-nethol 50 mg tablet","author":"Aspen","year":"2020","unstructured":"Aspen. Summary of product characteristics, puri-nethol 50 mg tablet. Dublin: Aspen Pharma Trading Limited; 2020."},{"key":"1045_CR13","volume-title":"Summary of product characteristics, mezavant 1200 mg","author":"Shire","year":"2020","unstructured":"Shire. Summary of product characteristics, mezavant 1200 mg. Dublin: Shire Pharmaceuticals Ireland Limited; 2020."},{"key":"1045_CR14","volume-title":"Summary of product characteristics, mesalazine aurobindo 250 mg, zetpillen","author":"Aurobindo","year":"2019","unstructured":"Aurobindo. Summary of product characteristics, mesalazine aurobindo 250 mg, zetpillen. Baarn: Aurobindo Pharma B.V; 2019."},{"key":"1045_CR15","volume-title":"Summary of product characteristics, methotrexate accord 20 mg, tablets","author":"Accord","year":"2020","unstructured":"Accord. Summary of product characteristics, methotrexate accord 20 mg, tablets. Haarlem: Accord Healthcare B.V; 2020."},{"key":"1045_CR16","volume-title":"Summary of product characteristics, thiosix 10\u201320 mg","author":"Teva","year":"2019","unstructured":"Teva. Summary of product characteristics, thiosix 10\u201320 mg. Haarlem: Teva Nederland BV; 2019."},{"key":"1045_CR17","volume-title":"Summary of Product Characteristics, Methotrexate Basic Pharma 5 mg = 0,133 ml","author":"BasicPharma","year":"2020","unstructured":"BasicPharma. Summary of Product Characteristics, Methotrexate Basic Pharma 5 mg = 0,133 ml. Geleen: Basic Pharma Manufacturing B.V; 2020."},{"key":"1045_CR18","volume-title":"Summary of Product Characteristics, Entyvio 300 mg poeder voor concentraat voor oplossing voor infusie","author":"Takeda","year":"2018","unstructured":"Takeda. Summary of Product Characteristics, Entyvio 300 mg poeder voor concentraat voor oplossing voor infusie. Vallensbaek Strand: Takeda Pharma A\/S; 2018."},{"key":"1045_CR19","volume-title":"Summary of product characteristics, imponi 45 mg\/0.45 ml oplossing voor injectie in een voorgevulde pen","author":"Janssen-Cilag","year":"2009","unstructured":"Janssen-Cilag. Summary of product characteristics, imponi 45 mg\/0.45 ml oplossing voor injectie in een voorgevulde pen. Leiden: Janssen Biologicals B.V; 2009."},{"key":"1045_CR20","volume-title":"Summary of product characteristics, STELARA 130 mg concentraat voor oplossing voor infusie","author":"Janssen-Cilag","year":"2009","unstructured":"Janssen-Cilag. Summary of product characteristics, STELARA 130 mg concentraat voor oplossing voor infusie. Leiden: Janssen Biologics B.V; 2009."},{"issue":"11","key":"1045_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/apt.15730","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, Savelkoul E, Gabriels RY, Simsek M, Dijkstra G, Pierik MJ, de Boer NKHL, Hoentjen F, et al. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2020;51(11):1076\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1045_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","volume":"149","author":"MJ Coenen","year":"2015","unstructured":"Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907\u201317.e7.","journal-title":"Gastroenterology."},{"issue":"9","key":"1045_CR23","first-page":"981","volume":"52","author":"FS Macaluso","year":"2017","unstructured":"Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, et al. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scand J Gastroenterol. 2017;52(9):981\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"1045_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/apt.15458","volume":"50","author":"M Calafat","year":"2019","unstructured":"Calafat M, Ma\u00f1osa M, Ca\u00f1ete F, Ricart E, Iglesias E, Calvo M, ENEIDA registry of GETECCU, et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 2019;50(7):780\u20138.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"1045_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2036.2008.03925.x","volume":"29","author":"U Hindorf","year":"2009","unstructured":"Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29(6):654\u201361.","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"1045_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","volume":"12","author":"NKH de Boer","year":"2018","unstructured":"de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2018;12(5):610\u201320.","journal-title":"J Crohns Colitis."},{"issue":"1","key":"1045_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/apt.15280","volume":"50","author":"M Simsek","year":"2019","unstructured":"Simsek M, Deben DS, Horjus CS, Benard MV, Lissenberg-Witte BI, Buiter HJC, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther. 2019;50(1):54\u201365.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"1045_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/gut.2005.074930","volume":"55","author":"U Hindorf","year":"2006","unstructured":"Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55(10):1423\u201331.","journal-title":"Gut"},{"issue":"2","key":"1045_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2036.2006.02977.x","volume":"24","author":"U Hindorf","year":"2006","unstructured":"Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(2):331\u201342.","journal-title":"Aliment Pharmacol Ther."},{"issue":"41","key":"1045_CR30","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1097\/MD.0000000000001513","volume":"94","author":"Y Qiu","year":"2015","unstructured":"Qiu Y, Mao R, Zhang SH, Li MY, Guo J, Chen BL, et al. Safety profile of thiopurines in crohn disease: analysis of 893 patient-years follow-up in a Southern China Cohort. Medicine (Baltimore). 2015;94(41):e1513.","journal-title":"Medicine (Baltimore)."},{"issue":"11","key":"1045_CR31","first-page":"688","volume":"13","author":"DT Rubin","year":"2017","unstructured":"Rubin DT. Recent research on joint pain and arthritis in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13(11):688\u201390.","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"5","key":"1045_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01045-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01045-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01045-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T18:57:33Z","timestamp":1671044253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01045-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01045-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"15 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for the development and implementation of IBDREAM was obtained from the Netherlands Organisation for Health Research and Development (ZonMW, Grant number 836042002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elaine L. Giraud, Pepijn W.A. Thomas, Jette A. van Lint, Eugene P. van Puijenbroek, Tessa E.H. R\u00f6mkens, Maurice G.V.M. Russel, Jeroen M. Jansen, Naomi T. Jessurun, and Frank Hoentjen declare they have no conflicts of interest. Rachel L. West reports that she has participated in advisory boards and\/or received financial compensation from Janssen and Pfizer, all outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study protocol was approved by the Radboudumc Medical Ethical Committee [2015-2245].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients signed written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors provided consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The dataset analysed during the current study is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors read and approved the final version of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}